Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Cubist Pharmaceuticals

This page shows the latest Cubist Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

Merck prepares filings for Clostridium antibody

Merck prepares filings for Clostridium antibody

Merck bolstered its anti-infectives pipeline last year with the $8.4bn acquisition of Cubist Pharmaceuticals, which added a range of antibiotics including recently-approved Sivextro (tedizolid phosphate) and Zerbaxa

Latest news

  • Merck hopes for another Keytruda with new immunotherapy deal Merck hopes for another Keytruda with new immunotherapy deal

    Merck also said it expects to see an increase in overall revenue from its recent $8.4bn purchase of Cubist Pharmaceuticals, the maker of blockbuster antibiotic Cubicin, which made $480m.

  • Actavis gets FDA nod for new antibiotic Actavis gets FDA nod for new antibiotic

    Avycaz' closest rival among these is Cubist Pharmaceuticals' Zerbaxa (ceftolozane/tazobactam) - which has been tipped as a $1bn-plus product - while the others are Cubist's Sivextro (tedizolid), Durata/Actavis' Dalvance

  • Antibiotics among 7 new drugs backed by EMA Antibiotics among 7 new drugs backed by EMA

    The Medicines Company’s Orbactiv and Cubist’s Sivextro set for European approval. ... Both The Medicines Company's Orbactiv (oritavancin) and Cubist's Sivextro (tedizolid phosphate) were among seven new medicines backed by EMA scientific advisers in

  • FDA backs Cubist's antibiotic Zerbaxa FDA backs Cubist's antibiotic Zerbaxa

    Combination cephalosporin and beta lactamase inhibitor wins US approval. Cubist Pharmaceuticals has rounded off a busy few months with its second approval for a new antibiotic, this time getting FDA approval ... The drug was filed in Europe for the same

  • Merck stumps up $375m for cancer firm OncoEthix Merck stumps up $375m for cancer firm OncoEthix

    Follows $8.4bn deal to buy Cubist. Merck &Co has bolstered its cancer pipeline with the acquisition of Swiss biopharma company OncoEthix in a deal valued at up to $375m. ... tumours. The acquisition is Merck's second this month after it agreed an $8.4bn

More from news
Approximately 10 fully matching, plus 12 partially matching documents found.

Latest Intelligence

  • Curbing the rise of drug resistance Curbing the rise of drug resistance

    Rekindling anti-microbial innovation . Although doctors and veterinarians (and, indirectly, patients) have a responsibility to cut back the volume of antibiotic prescriptions, it is the pharmaceuticals sector that holds the greatest ... The KPMG report

  • Cubist: Meeting the challenge in antibiotics Cubist: Meeting the challenge in antibiotics

    Patrick Vink on Cubist Pharmaceuticals’ ambitions in anti-infectives, which have attracted the attention of Merck &Co. ... Cubist expansion. One company that has remained in the field despite these difficulties is US-based Cubist Pharmaceuticals, which

  • Deal Watch table for July 2013 Deal Watch table for July 2013

    8, 600. Trius Therapeutics / Cubist Pharmaceuticals. Acquisition. Antibiotic pipeline inc TR-701 (tedizolid phosphate, p3). ... 815. Optimer Pharmaceuticals / Cubist Pharmaceuticals. Acquisition. Antibiotic pipeline based on Dificid (fidaxomicin) for

  • Pharma deals during July 2013 Pharma deals during July 2013

    Whilst the Elan and Perrigo deal creates a diversified business, several companies, such as Cubist, Ipsen and Spectrum Pharmaceuticals, focused on acquiring assets to bolster their core business areas in antibiotics, ... On the same day, Cubist announced

  • Pharma deals during March 2013 Pharma deals during March 2013

    Paying $25m upfront in cash, Cubist Pharmaceuticals is buying the rights to ceftolozane in certain Asia-Pacific and Middle East territories from Astellas. ... Astellas Pharma/ Cubist Pharmaceuticals ††. Acquisition of rights. Ceftolozane for

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

  • Constellation Pharmaceuticals appoints Emma Reeve as CFO Constellation Pharmaceuticals appoints Emma Reeve as CFO

    US-based Constellation Pharmaceuticals has appointed Emma Reeve as its chief financial officer to bolster the biopharma’s finance efforts. ... Prior to that he spent ten years at Cubist Pharmaceuticals, Biogen and Covance.

  • Nabriva Therapeutics appoints new chief commercial officer Nabriva Therapeutics appoints new chief commercial officer

    Prior to serving MSD as its acting vice president, global brand leader anti-infective portfolio, he was vice president, international marketing for the anti-infectives portfolio at Cubist Pharmaceuticals.

  • Caligor Rx appoints Michael Dallmann as director of strategic planning Caligor Rx appoints Michael Dallmann as director of strategic planning

    He brings experience from Cubist Pharmaceuticals and Peninsula Pharmaceuticals. New Jersey-based Caligor Rx has named Michal Dallman to the newly-created role of as director of strategic planning. ... Dallmann - who has over two decades of pharmaceutical

  • Cubist’s Dr Lorianne Masuoka jumps ship to InVivo Cubist’s Dr Lorianne Masuoka jumps ship to InVivo

    Comes amidst MSD’s recent takeover of the antibiotic specialist. InVivo Therapeutics has appointed former Cubist executive team leader Dr Lorianne Masuoka as its new chief medical officer. ... She takes over from the interim CMO, Lou Vaickus. Prior to

  • Cubist picks Robert Perez as its new CEO Cubist picks Robert Perez as its new CEO

    He replaces Michael Bonney who will continue as chair. Antibiotic specialist Cubist Pharmaceuticals has announced that CEO Michael Bonney will step down from his position at the end of this year ... Cubist's ambitions have been seen with a number of drug

More from appointments
Approximately 1 fully matching, plus 4 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
fox&cat

up to your ears in it? some pressure is helpful but too much of the wrong sort quickly takes its...

Latest intelligence

01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?
The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.
Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....

Quick links

Infographics

Multimedia